Attention:

Certain features of sigmaaldrich.com will be down for maintenance Saturday afternoon/evening, February 24th starting at 3:00 pm CT until 9:00 pm CT.

Please note that you still have telephone and email access to our local offices. We apologize for any inconvenience.

NMDA Agonists

Product #

Image

Description

Biochem/physiol Actions

Add to Cart

A0430 1-Aminocyclopropanecarboxylic acid hydrochloride ≥98% NMDA glutamate receptor agonist acting at the glycine site
A3903 1-Aminocyclopropanecarboxylic acid ≥98% (TLC) NMDA agonist acting at the glycine site
C6880 D-Cycloserine powder Mode of Action: Inhibits cell wall biosynthesis (D-Ala peptide bond formation). Also prevents conversion of D-Ala to L-Ala. Bacteriostatic.
Partial agonist at the glycine modulatory site of NMDA glutamatergic receptors; antibiotic against Gram-negative bacteria.
Mode of Resistance: D-Ala transport interference.
C3909 D-Cycloserine synthetic Mode of Action: Inhibits cell wall biosynthesis (D-Ala peptide bond formation). Also prevents conversion of D-Ala to L-Ala. Bacteriostatic.
Partial agonist at the glycine modulatory site of NMDA glutamatergic receptors; antibiotic against Gram-negative bacteria.
Mode of Resistance: D-Ala transport interference.
C8005 D-Cysteine hydrochloride monohydrate ≥98% (TLC)  
C7880 L-Cysteine hydrochloride monohydrate reagent grade, ≥98% (TLC) NMDA glutamatergic receptor antagonist.
C1276 L-Cysteine hydrochloride anhydrous, ≥98% (TLC) NMDA glutamatergic receptor agonist that is also an agonist at AMPA glutamatergic receptors at high concentrations.
H9633 L-Homocysteic acid L-Homocysteic acid (L-HCA) is an endogenous neurotransmitter ligand of NMDA (N-methyl-D-aspartate) receptors. It is an analog of glutamate and competitively suppresses glutamate-cystine (xc-) antiporter function in neurons, causing decrease in cysteine uptake.
SML0229   CIQ ≥98% (HPLC) CIQ is positive allosteric modulator of NR2C/NR2D subunit containing NMDA receptors. CIQ increases channel opening frequency of recombinant NR2Cor NR2D containing receptors by two-fold (EC50 = 2.7 and 2.8 μM, respectively), with no effect on NR2A or NR2B subtypes. The compound does not alter the EC50 values for glutamate or glycine on channel opening.
D1068 DCB ≥98% (HPLC), solid Neutral allosteric modulator of the metabotropic glutamate receptor mGluR5.
G7795 Ganaxolone solid Ganaxolone (3alpha-hydroxy-3beta-methyl-5alpha-pregnane-20-one) is a positive allosteric modulator of the GABAA receptor subtype; synthetic analog of the endogenous neurosteroid allopregnanolone; effective against chemically induced seizures in rats and mice. Ganaxolone is an orally active analog of allopregnanolone that is not converted to the hormonally active 3-keto form. The enhanced anticonvulsant potency of ganaxolone after neurosteroid withdrawal supports the use of ganaxolone as a specific treatment for perimenstrual catamenial epilepsy.
L1170 LY-487379 hydrochloride ≥98% (HPLC) LY-487379 is a positive allosteric modulator of the metabotropic glutamate receptor mGluR2. EC50 = 1.7 μM. LY-487379 shows no intrinsic agonist or antagonist activity at hmGluR2 and has no activity at human mGluR3. LY-487379 markedly potentiates glutamate-stimulated [35S]GTPγS binding in a concentration-dependent manner at hmGluR2, shifting the glutamate dose-response curve leftward by 3-fold and increasing the maximum levels of [35S]GTPγS stimulation. LY-487379 has anxiolytic effects in fear-potentiated startle. This activity profile is useful in all symptom domains of schizophrenia.
M3262 N-Methyl-D-aspartic acid ≥98% (TLC), solid Excitotoxic amino acid. Prototypic agonist at the NMDA-type glutamate receptor that regulates ion channels; important in long-term potentiation, ischemia, and epilepsy.
N-Methyl-D-aspartic acid (NMDA) plays a crucial role in release of luteinizing hormone and PRL (prolactin) in the pituitary gland and GnRH (gonadotropin releasing hormone) in the hypothalamus. It acts as a specific agonist for NMDA type glutamate receptors.
P1999 PEAQX tetrasodium hydrate ≥98% (HPLC) NMDA receptor antagonist.